Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.3.4 was published, replacing the previous v3.3.3. No visible changes to the study details or page layout are indicated by the screenshot.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedNew location sections were added for California, Illinois, Massachusetts, New York, and Nouvelle-Aquitaine and old location sections were removed; the revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

- Check55 days agoChange DetectedRevision updated to v3.3.2 (replacing v3.2.0) on the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedThe funding status disclaimer that warned about updates and operating status was removed. The page now solely presents the study details and related information.SummaryDifference0.2%

- Check70 days agoChange DetectedUpdated the Locations entry to replace 'Tainan City, Taiwan, 70403' with 'Tainan, Taiwan, 70403'.SummaryDifference0.0%

- Check77 days agoChange DetectedNo significant content changes were detected; observed differences appear to be minor formatting adjustments that do not affect the study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.